{"id":"W4400272940","doi":"10.1200/jco.2024.42.16_suppl.tps4192","title":"A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Iterion Therapeutics","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Cancer research; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007809938,0.00159899,0.001409834,0.0004111332,0.0004054825,0.0008382401,0.0006440624,0.001155271,0.005343966],"category_scores_gemma":[0.000446282,0.0006074242,0.000982731,0.0003994345,0.0006400235,0.0006710376,0.0003143768,0.002440777,0.00138143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001168339,"about_ca_system_score_gemma":0.001700429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002248631,"about_ca_topic_score_gemma":0.00754135,"domain_scores_codex":[0.9997981,0.00007415695,0.000007410446,0.00004413788,0.00002293151,0.00005331523],"domain_scores_gemma":[0.9996998,0.00002538762,0.00004475024,0.00002339673,0.00002427674,0.0001823039],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5275968,0.1195315,0.006446726,0.001958011,0.00159504,0.0007828441,0.0003950818,0.005620806,0.1565702,0.0006965313,0.01377113,0.1650352],"study_design_scores_gemma":[0.4440779,0.5207859,0.0111768,0.00007221663,0.0006239683,0.001090182,0.000138834,0.002228723,0.01090955,0.0004646261,0.008383235,0.00004815397],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796109,0.003435268,0.001498263,0.0008542292,0.0002463183,0.006417316,0.003917571,0.0002696959,0.003750495],"genre_scores_gemma":[0.9708858,0.003718594,0.004020881,0.001289392,0.0001452923,0.005543383,0.005623732,0.00006993353,0.008703103],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005343966,"threshold_uncertainty_score":0.0178774,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0453222427616434,"score_gpt":0.3728658826136667,"score_spread":0.3275436398520233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}